TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29764875

Group type: EXPERIMENTAL
Intervention: High-dose GHX02 (1920 mg/day)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Standard-dose GHX02 (960 mg/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 29764880

Group type: EXPERIMENTAL
Intervention: Digital breast tomosynthesis plus synthesised images (DBT+s2D)
Number of subjects: 80000

Group type: COMPARATOR
Intervention: Standard full-field digital mammography (FFDM)
Number of subjects: 80000
Study: 29764889

Group type: EXPERIMENTAL
Intervention: Autologous cultured mesenchymal stem cells (MSCs) implanted into the area of mid-portion AT.
Number of subjects: 10
Study: 29764892

Group type: EXPERIMENTAL
Intervention: Supervised high-intensity aerobic and resistance exercise
Number of subjects: 866

Group type: COMPARATOR
Intervention: Self-directed exercise (provision of guidelines)
Number of subjects: 866
Study: 29764958

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No diabetes mellitus (Control group)
Number of subjects: 0
Study: 29765401

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF) training, 15 double training sessions
Number of subjects: 48
Study: 29765616

Group type: EXPERIMENTAL
Intervention: Cumulative steroid exposure (dose and duration) categorized into four levels: 0g (no exposure), >0 and <3.65g (<10mg/day for a year), ≥3.65g and <18.25g (1-5 years at 10mg/day), and ≥18.25g (>5 years at 10mg/day).
Number of subjects: 409
Study: 29766026

Group type: EXPERIMENTAL
Intervention: Intrathecal AAV9 Gene Therapy
Number of subjects: 0
Study: 29766087

Group type: EXPERIMENTAL
Intervention: Definitive fascial closure of the laparotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Damage control laparotomy (DCL)
Number of subjects: 0
Study: 29766088

Group type: EXPERIMENTAL
Intervention: Community consultation (CC) process using random digit dialing technique
Number of subjects: 500
Study: 29766134

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) at index admission within 24 hours of presentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) after clinical resolution
Number of subjects: 0
Study: 29766216

Group type: EXPERIMENTAL
Intervention: ACEi/ARB at ICU discharge
Number of subjects: 1551

Group type: COMPARATOR
Intervention: No ACEi/ARB at ICU discharge
Number of subjects: 1551
Study: 29766308

Group type: EXPERIMENTAL
Intervention: Robotic TAPP (r-TAPP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Laparoscopic TAPP (l-TAPP)
Number of subjects: 50
Study: 29766322

Group type: EXPERIMENTAL
Intervention: Microvascular Flow Index (MFI) < 2.6
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Abnormal MFI on day 1
Number of subjects: 97

Group type: COMPARATOR
Intervention: Routine daily microcirculatory monitoring
Number of subjects: 97
Study: 29766337

Group type: EXPERIMENTAL
Intervention: ASLAN-002 at 300 mg BID
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ASLAN-002 at 450 mg BID
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ASLAN-002 (all doses)
Number of subjects: 40
Study: 29766383

Group type: EXPERIMENTAL
Intervention: Food insufficiency
Number of subjects: 0
Study: 29766456

Group type: EXPERIMENTAL
Intervention: dNLR ≥ 1.35 in hormone receptor-negative/HER2+ population
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: dNLR ≥ 1.35 in patients with one to three lymph node metastases
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: dNLR in non-luminal tumors
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: dNLR in HER2-enriched tumors
Number of subjects: 1246
Study: 29766812

Group type: EXPERIMENTAL
Intervention: Tofogliflozin
Number of subjects: 19
Study: 29766854

Group type: EXPERIMENTAL
Intervention: Basket catheter deployment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Basket catheter peak-to-peak voltage measurement
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Electrogram stability and organization
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Overall assessment of basket catheters
Number of subjects: 25
Study: 29766871

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 418

Group type: COMPARATOR
Intervention: Fludrocortisone
Number of subjects: 418

Group type: COMPARATOR
Intervention: Placebo (for both metoprolol and fludrocortisone)
Number of subjects: 418

Group type: COMPARATOR
Intervention: General driving population (U.S., U.K., Canada)
Number of subjects: 418
Study: 29766873

Group type: EXPERIMENTAL
Intervention: Quadripolar CRT system (Quartet LV lead)
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Bipolar CRT lead system (BiP group)
Number of subjects: 1078
Study: 29766891

Group type: EXPERIMENTAL
Intervention: Continuous heparin infusion
Number of subjects: 333

Group type: COMPARATOR
Intervention: Intermittent heparin infusion
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Patients on NOACs
Number of subjects: 333

Group type: COMPARATOR
Intervention: Patients on warfarin
Number of subjects: 333
Study: 29766894

Group type: EXPERIMENTAL
Intervention: ICD lead monitoring during LVAD implantation
Number of subjects: 32
Study: 29767680

Group type: COMPARATOR
Intervention: African-American women
Number of subjects: 66

Group type: COMPARATOR
Intervention: Physical activity, substrate oxidation, and metabolic biomarkers
Number of subjects: 66
Study: 29767732

Group type: EXPERIMENTAL
Intervention: Dietary intake of α-linolenic acid (ALA)
Number of subjects: 57053
Study: 29767735

Group type: EXPERIMENTAL
Intervention: Banana and dopamine 3-O-sulfate
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: Dopamine 4-O-sulfate
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: Garlic and alliin
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: N-acetylalliin
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: S-allylcysteine
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: Unannotated metabolite X-02269 for dark fish intake
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: Unannotated metabolite X-21442 for coffee intake
Number of subjects: 1369
Study: 29767845

Group type: EXPERIMENTAL
Intervention: Defibrotide treatment after HSCT
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Defibrotide treatment in paediatric patients
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Defibrotide treatment in adult patients
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Defibrotide treatment without multi-organ dysfunction (MOD)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Earlier initiation of defibrotide treatment after VOD/SOS diagnosis
Number of subjects: 1000
Study: 29768274

Group type: EXPERIMENTAL
Intervention: Titrated quantitative conjunctival provocation test (CPT)
Number of subjects: 23
Study: 29768372

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention program including wearable devices, App for recording activities, counseling, physical activity program, and pelvic floor treatment.
Number of subjects: 0
Study: 29768438

Group type: EXPERIMENTAL
Intervention: BMI ≥25.1 kg/m2
Number of subjects: 2833

Group type: EXPERIMENTAL
Intervention: BMI >25.1 kg/m2 in male patients
Number of subjects: 2833

Group type: EXPERIMENTAL
Intervention: Increased BMI after 12 months and high serum creatinine
Number of subjects: 2833

Group type: COMPARATOR
Intervention: Baseline and follow-up BMI in female patients
Number of subjects: 2833
Study: 29768645

Group type: EXPERIMENTAL
Intervention: Endoscopic resection of LSL-P
Number of subjects: 125

Group type: COMPARATOR
Intervention: Ampullary adenomas
Number of subjects: 125
Study: 29769025

Group type: EXPERIMENTAL
Intervention: Urine culture performed in practice
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Urine culture performed at hospital
Number of subjects: 488

Group type: COMPARATOR
Intervention: No culture performed
Number of subjects: 488
Study: 29769049

Group type: EXPERIMENTAL
Intervention: Screening for sleep-disordered breathing (SDB) using a two-channel screening system (ApneaLink™)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patients with moderate to severe SDB
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI) assessment
Number of subjects: 100
Study: 29769127

Group type: EXPERIMENTAL
Intervention: Robotic indices provided by a novel robotic device for upper limb rehabilitation
Number of subjects: 48
Study: 29769174

Group type: EXPERIMENTAL
Intervention: Lark (virtual coaching app with JITAI features)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MyFitnessPal (self-help calorie-counting app)
Number of subjects: 0
Study: 29769232

Group type: EXPERIMENTAL
Intervention: Active compression-decompression (ACD) CPR
Number of subjects: 10

Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ACD-CPR and Manual CPR
Number of subjects: 10
Study: 29769385

Group type: EXPERIMENTAL
Intervention: Panitumumab plus Irinotecan (Pa 9 mg/m)
Number of subjects: 18
Study: 29770461

Group type: EXPERIMENTAL
Intervention: Autonomous motivation
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Controlled motivation
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 136
Study: 29770625

Group type: EXPERIMENTAL
Intervention: Loop electrosurgical excision procedure/conization
Number of subjects: 69741

Group type: COMPARATOR
Intervention: Various management strategies (colposcopy, cervical biopsies and/or endocervical curettage, cryotherapy)
Number of subjects: 69741

Group type: EXPERIMENTAL
Intervention: Previous screening history >5 years from present ASCUS diagnosis
Number of subjects: 69741

Group type: COMPARATOR
Intervention: Repeat cervical smears
Number of subjects: 69741
Study: 29770748

Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL) therapy for 8 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (unchanged cART regimen) for 8 weeks
Number of subjects: 22
Study: 29771158

Group type: EXPERIMENTAL
Intervention: Smoker (SMK)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Moist Snuff Consumer (MSC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-Tobacco Consumer (NTC)
Number of subjects: 120
Study: 29771283

Group type: EXPERIMENTAL
Intervention: High-risk adolescents consuming high-sugar milkshake
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: High-risk adolescents consuming milkshakes (all variants)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Low-risk adolescents consuming milkshakes (all variants)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: High-fat milkshake
Number of subjects: 108
Study: 29771289

Group type: EXPERIMENTAL
Intervention: Plasma trigonelline concentrations after coffee consumption
Number of subjects: 3503

Group type: EXPERIMENTAL
Intervention: Plasma trigonelline as a marker of coffee intake
Number of subjects: 3503

Group type: EXPERIMENTAL
Intervention: Within-person reproducibility of plasma trigonelline
Number of subjects: 3503

Group type: EXPERIMENTAL
Intervention: Coffee consumption and plasma concentrations of niacin vitamers
Number of subjects: 3503
Study: 29773527

Group type: EXPERIMENTAL
Intervention: Scheduled SMS
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: SMS triggered by missed or delayed doses
Number of subjects: 63

Group type: COMPARATOR
Intervention: No SMS
Number of subjects: 63
Study: 29773572

Group type: EXPERIMENTAL
Intervention: Pathogen-inactivated platelets (using riboflavin and UV B illumination technology)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Standard plasma-stored platelets
Number of subjects: 469
Study: 29773593

Group type: EXPERIMENTAL
Intervention: Bosutinib
Number of subjects: 284
Study: 29773601

Group type: EXPERIMENTAL
Intervention: Combinatorial targeting of XPO1 and FLT3
Number of subjects: 0
Study: 29773661

Group type: EXPERIMENTAL
Intervention: Oncolytic Vaccinia Virus GL-ONC1
Number of subjects: 0
Study: 29773698

Group type: EXPERIMENTAL
Intervention: Amino acid-based formula (AAF) for 2 weeks followed by an open food challenge (OFC) with standard cow's milk formula and a home challenge for another 2 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline CoMiSS score before AAF treatment.
Number of subjects: 0
Study: 29773699

Group type: EXPERIMENTAL
Intervention: Immediate transfer group (FET performed in the first cycle following stimulated IVF)
Number of subjects: 724

Group type: COMPARATOR
Intervention: Delayed transfer group (FET performed at least in the second cycle following stimulated IVF)
Number of subjects: 724
Study: 29773949

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAT)
Number of subjects: 3420
Study: 29773969

Group type: EXPERIMENTAL
Intervention: Umeclidinium (UMEC) 62.5 mcg
Number of subjects: 0
Study: 29774030

Group type: EXPERIMENTAL
Intervention: CSF-470 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medium-dose IFNα2b
Number of subjects: 0
Study: 29774051

Group type: EXPERIMENTAL
Intervention: Alosetron
Number of subjects: 0
Study: 29774169

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision.
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily
Number of subjects: 57
Study: 29775078

Group type: EXPERIMENTAL
Intervention: Developmental Reciprocity Treatment
Number of subjects: 22
Study: 29775807

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg on day 1 (21-day cycles)
Number of subjects: 138
Study: 29776017

Group type: EXPERIMENTAL
Intervention: PF-04236921 (anti-interleukin-6 monoclonal antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-04236921
Number of subjects: 0
Study: 29776373

Group type: EXPERIMENTAL
Intervention: 2 mg/kg intravenously, weekly pegylated recombinant arginase (BCT-100)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control samples (not specified)
Number of subjects: 1
Study: 29776382

Group type: EXPERIMENTAL
Intervention: Radiostereometric Analysis (RSA)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Phantom study with RSA
Number of subjects: 7
Study: 29776789

Group type: EXPERIMENTAL
Intervention: Real cTBS (110% resting motor threshold, 3600 pulses, Fp1 location)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sham cTBS
Number of subjects: 49
Study: 29776897

Group type: EXPERIMENTAL
Intervention: SMS attendance-reminder for collective sessions strategy
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Facebook challenge group
Number of subjects: 262
Study: 29776920

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Invasive breast cancer
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Lymph node involvement
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Axillary dissection
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Personal income <€1900/month
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Not receiving the patient information booklet on RTW
Number of subjects: 178
Study: 29777016

Group type: EXPERIMENTAL
Intervention: e-ASPECTS scores (automated system for quantifying signs of infarction)
Number of subjects: 1480
Study: 29777230

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline CRP levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline CC levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline leptin levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline ghrelin levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decrease in leptin levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decrease in CC levels
Number of subjects: 0
Study: 29777235

Group type: EXPERIMENTAL
Intervention: 50% caloric restriction for 6 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Muscle UCP2 expression changes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gene expression changes in skeletal muscle and adipose tissue
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Altered catecholamine and FGF21 concentrations
Number of subjects: 12
Study: 29777299

Group type: EXPERIMENTAL
Intervention: Vismodegib
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1
Study: 29777373

Group type: EXPERIMENTAL
Intervention: CardioMEMS HF™ system
Number of subjects: 230
Study: 29777402

Group type: EXPERIMENTAL
Intervention: Asymptomatic systemic imaging during follow-up
Number of subjects: 10838

Group type: EXPERIMENTAL
Intervention: First follow-up year imaging
Number of subjects: 10838

Group type: EXPERIMENTAL
Intervention: Estrogen receptor/progesterone receptor-negative tumors
Number of subjects: 10838
Study: 29777631

Group type: EXPERIMENTAL
Intervention: Deferasirox + erythropoietin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Erythropoietin alone
Number of subjects: 23
Study: 29777735

Group type: EXPERIMENTAL
Intervention: Sleep bruxism assessment through questionnaires, clinical symptoms, and electromyographic/electrocardiographic data.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic stress assessment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjective sleep quality assessment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleep bruxism presence.
Number of subjects: 0
Study: 29777825

Group type: EXPERIMENTAL
Intervention: Magnetoencephalography (MEG) recordings from participants exposed to different exemplar images of the same object concepts.
Number of subjects: 32
Study: 29777865

Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antimuscarinics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switching therapy
Number of subjects: 0
Study: 29778365

Group type: EXPERIMENTAL
Intervention: Cerebral microbleeds
Number of subjects: 1490

Group type: COMPARATOR
Intervention: No cerebral microbleeds
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: Cerebral microbleeds and HAS-BLED score
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: Cerebral microbleeds, diabetes, anticoagulant type, and HAS-BLED
Number of subjects: 1490

Group type: COMPARATOR
Intervention: HAS-BLED score alone
Number of subjects: 1490
Study: 29778515

Group type: EXPERIMENTAL
Intervention: Fractional intradermal vaccination with quadrivalent conjugate vaccine (MenACWY-CRM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tetanus toxoid conjugated vaccine (Nimenrix®)
Number of subjects: 12
Study: 29778738

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (methotrexate, vincristine, cisplatin, and cyclophosphamide) with high-risk patients receiving additional vinblastine.
Number of subjects: 81
Study: 29779023

Group type: EXPERIMENTAL
Intervention: Patients with CKD
Number of subjects: 58

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups analyzed together
Number of subjects: 58
Study: 29779054

Group type: EXPERIMENTAL
Intervention: Higher intakes of fruits and vegetables and whole-grain products
Number of subjects: 922

Group type: COMPARATOR
Intervention: Lipid accumulation product
Number of subjects: 922
Study: 29779129

Group type: EXPERIMENTAL
Intervention: AFM-guided patients
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (manual GDFT strategy)
Number of subjects: 84
Study: 29779774

Group type: EXPERIMENTAL
Intervention: Repeated NALC/NaOH-decontamination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (single NALC/NaOH-decontamination)
Number of subjects: 0
Study: 29779835

Group type: EXPERIMENTAL
Intervention: Islet cell transplantation
Number of subjects: 23
Study: 29780001

Group type: EXPERIMENTAL
Intervention: Automated antigen-typing algorithm based on whole-genome sequencing (bloodTyper)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Improved bloodTyper algorithm
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Final bloodTyper algorithm
Number of subjects: 200
Study: 29780029

Group type: EXPERIMENTAL
Intervention: ABLE programme
Number of subjects: 30
Study: 29780263

Group type: EXPERIMENTAL
Intervention: Gel-200
Number of subjects: 1184

Group type: COMPARATOR
Intervention: PBS
Number of subjects: 1184
Study: 29780318

Group type: EXPERIMENTAL
Intervention: Exergaming intervention for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard exercise
Number of subjects: 0
Study: 29780414

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with trimethoprim-sulfamethoxazole
Number of subjects: 70

Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 70
Study: 29780848

Group type: EXPERIMENTAL
Intervention: Controlled human hookworm infection (CHHI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 29780852

Group type: EXPERIMENTAL
Intervention: ADS-5102 (amantadine) extended release capsules, 274 mg once daily at bedtime for up to two years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (in previous randomized controlled trial)
Number of subjects: 0
Study: 29781056

Group type: EXPERIMENTAL
Intervention: Pevonedistat with docetaxel (arm 1, n=22)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pevonedistat with carboplatin plus paclitaxel (arm 2, n=26)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pevonedistat with gemcitabine (arm 3, n=10)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Lead-in cohort for carboplatin dose (arm 2a, n=6)
Number of subjects: 64
Study: 29781237

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (Dysport®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NLRC model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed Model Repeated Measures analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation study
Number of subjects: 0
Study: 29781568

Group type: EXPERIMENTAL
Intervention: Left ventricular diastolic dysfunction (DD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Interventions to prevent or delay DD
Number of subjects: 20
Study: 29781833

Group type: EXPERIMENTAL
Intervention: Sociodemographic factors (age, sex, employment, profession, marital status)
Number of subjects: 3227

Group type: EXPERIMENTAL
Intervention: Sociodemographic factors (age, sex, employment, marital status)
Number of subjects: 3227
Study: 29781974

Group type: EXPERIMENTAL
Intervention: Shape-descriptive factors
Number of subjects: 201
Study: 29782179

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 367

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study: 29782642

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily (q12h) until month 3, then adjusted to either 5 or 10 mg q12h.
Number of subjects: 2867